

CIN No. L24221GJ1992PLC017054



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Phone : +91 92280 16100-03 | +91 79 2646 8653/7886, 2640 3214 | Fax : +91 79 2640 4961
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal.: Sanand, Dist.: Ahmedabad.
Email : ishitadrugs@gmail.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.in

May 29, 2015

The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Front
Mumbai - 400 001

Scrip Code : 524400

Dear Sir,

Sub: Adoption Codes for Fair Disclosure and Code of Conduct SEBI (Prohibition of Insider Trading) Regulation, 2015

This is to inform you that the Board of Directors of the Company in their meeting held on 29.5.2015 have formulated and adopted "Code for Fair Disclosure and Conduct" as per Regulation 8(1) and 9(1) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015

As required by Regulation 8(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, we hereby submit the "Code of Practices and Procedures for Fair Disclosure". This is also being published on the Company website.

Kindly take the same on record & oblige.

Thank you,

Your faithfully,

For Ishita Drugs & Industries Limited

(Authorised Signatory)



"Our basic drugs in the service of humanity worldwide"

D & B D-U-N-S Number - 85-018-0359

ISHITA DRUGS & INDUSTRIES LIMITED

CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION

[As per sub-regulation (1) of regulation 8 of the SEBI (Prohibition of insider Trading) Regulation 2015]

The Company will adhere to the following so as to ensure fair disclosure of events and occurrences that could impact price of its securities in the market :-

1. Prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being, in order to make such information generally available.
2. Uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.
3. Designation of a senior officer to deal with dissemination of unpublished price sensitive information.
4. Prompt dissemination of unpublished price sensitive information that gets disclosure selectively, inadvertently or otherwise, to make such information generally available.
5. Appropriate and fair response to queries on news reports and requests for verification of market rumors by regulatory authorities.
6. Ensuring that information shared with analysts and research personnel is not unpublished price sensitive information.
7. Developing best practices to make transcripts or records of proceedings of meetings with analysts and other investor relation conferences on the official website to ensure official confirmation and documentation of disclosures made.
8. Handling of all unpublished price sensitive information on a need-to-know basis.



[Handwritten signature]